These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Infarction prophylaxis--prevention of the sudden heart death? An alternative]. Gross F MMW Munch Med Wochenschr; 1982 May; 124(18):435-6. PubMed ID: 6124885 [No Abstract] [Full Text] [Related]
4. Reduction in cardiac death and reinfarction rates caused by beta-blockers after acute myocardial infarction. Ribeiro LG; Ruzyłło W Kardiol Pol; 1983; 26(4):281-6. PubMed ID: 6138457 [No Abstract] [Full Text] [Related]
5. Advice for management of the long-QT patient. Donahue JK J Cardiovasc Electrophysiol; 2010 Aug; 21(8):902-4. PubMed ID: 20455972 [No Abstract] [Full Text] [Related]
6. Invasive electrophysiologic studies as predictor of sudden death and for treatment of patients with aborted sudden death. Scheinman MM Cardiologia; 1990 Jan; 35(1 Suppl):55-60. PubMed ID: 1982245 [No Abstract] [Full Text] [Related]
7. Sudden cardiac death and the potential role of beta-adrenoceptor-blocking drugs. Rajman I; Kendall MJ Postgrad Med J; 1993 Dec; 69(818):903-11. PubMed ID: 7907178 [TBL] [Abstract][Full Text] [Related]
8. The role of beta-adrenergic blocking agents in preventing sudden cardiac death. Pitt B Circulation; 1992 Jan; 85(1 Suppl):I107-11. PubMed ID: 1345815 [TBL] [Abstract][Full Text] [Related]
9. [Beta-blocking drugs for the treatment of hypertension (author's transl)]. Garnier B Schweiz Rundsch Med Prax; 1975 Nov; 64(45):1452-4. PubMed ID: 241989 [No Abstract] [Full Text] [Related]
10. Sudden cardiac death and the potential role of beta adrenoceptor-blocking drugs. Jolobe OM Postgrad Med J; 1994 Jul; 70(825):521-2. PubMed ID: 7937438 [No Abstract] [Full Text] [Related]
11. [Beta receptor blockers in the therapy of coronary disease]. Rettig G ZFA (Stuttgart); 1980 Mar; 56(9):600-5. PubMed ID: 6103604 [No Abstract] [Full Text] [Related]
12. Beta-adrenoceptor blocking agents for the treatment of heart failure. Heilbron BG; Gin KG Int J Clin Pharmacol Ther; 1996 Jun; 34(6):231-5. PubMed ID: 8793609 [TBL] [Abstract][Full Text] [Related]
13. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Ellison KE; Gandhi G Drugs; 2005; 65(6):787-97. PubMed ID: 15819591 [TBL] [Abstract][Full Text] [Related]
14. The role of beta-blockers in the treatment of patients after infarction. Pratt CM; Young JB; Roberts R Cardiol Clin; 1984 Feb; 2(1):13-20. PubMed ID: 6152718 [TBL] [Abstract][Full Text] [Related]
15. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. Goldenberg I; Bradley J; Moss A; McNitt S; Polonsky S; Robinson JL; Andrews M; Zareba W; J Cardiovasc Electrophysiol; 2010 Aug; 21(8):893-901. PubMed ID: 20233272 [TBL] [Abstract][Full Text] [Related]
16. The selection of antiarrhythmic regimens by electrophysiologic studies: techniques and results. Horowitz LN; Spielman SR; Greenspan AM; Webb CR Cardiovasc Clin; 1985; 15(3):187-97. PubMed ID: 2870804 [No Abstract] [Full Text] [Related]
19. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Lemmer B Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of different beta-blockers in the treatment of long QT syndrome. Abu-Zeitone A; Peterson DR; Polonsky B; McNitt S; Moss AJ J Am Coll Cardiol; 2014 Sep; 64(13):1352-8. PubMed ID: 25257637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]